Zurich Cantonal Bank’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-27,921
| Closed | -$1.12M | – | 2557 |
|
|
2026
Q1 | $1.12M | Buy |
+27,921
| New | +$602K | ﹤0.01% | 1360 |
|
|
2025
Q4 | – | Sell |
-21,317
| Closed | -$500K | – | 2611 |
|
|
2025
Q3 | $482K | Buy |
21,317
+2,189
| +11% | +$51.1K | ﹤0.01% | 1758 |
|
|
2025
Q2 | $331K | Sell |
19,128
-763
| -4% | -$14.1K | ﹤0.01% | 1899 |
|
|
2025
Q1 | $435K | Sell |
19,891
-457
| -2% | -$12.6K | ﹤0.01% | 1681 |
|
|
2024
Q4 | $649K | Buy |
20,348
+1,136
| +6% | +$34.2K | ﹤0.01% | 1477 |
|
|
2024
Q3 | $554K | Sell |
19,212
-402
| -2% | -$14.9K | ﹤0.01% | 1499 |
|
|
2024
Q2 | $752K | Buy |
19,614
+2,635
| +16% | +$119K | ﹤0.01% | 1211 |
|
|
2024
Q1 | $998K | Sell |
16,979
-3,144
| -16% | -$200K | ﹤0.01% | 1065 |
|
|
2023
Q4 | $1.2M | Buy |
20,123
+6,102
| +44% | +$310K | ﹤0.01% | 969 |
|
|
2023
Q3 | $533K | Buy |
14,021
+1,310
| +10% | +$57.5K | ﹤0.01% | 1362 |
|
|
2023
Q2 | $1.16M | Buy |
12,711
+1,050
| +9% | +$90.6K | 0.01% | 880 |
|
|
2023
Q1 | $769K | Buy |
11,661
+1,026
| +10% | +$59.2K | ﹤0.01% | 1031 |
|
|
2022
Q4 | $550K | Sell |
10,635
-880
| -8% | -$46.7K | ﹤0.01% | 1208 |
|
|
2022
Q3 | $786K | Buy |
11,515
+1,107
| +11% | +$65.5K | ﹤0.01% | 939 |
|
|
2022
Q2 | $471K | Sell |
10,408
-1,219
| -10% | -$55.6K | ﹤0.01% | 1261 |
|
|
2022
Q1 | $591K | Sell |
11,627
-2,042
| -15% | -$90.1K | ﹤0.01% | 1248 |
|
|
2021
Q4 | $646K | Buy |
13,669
+6,353
| +87% | +$250K | ﹤0.01% | 1267 |
|
|
2021
Q3 | $241K | Buy |
7,316
+13
| +0.2% | +$730 | ﹤0.01% | 1796 |
|
|
2021
Q2 | $462K | Buy |
7,303
+82
| +1% | +$4.23K | ﹤0.01% | 1272 |
|
|
2021
Q1 | $310K | Sell |
7,221
-905
| -11% | -$42.8K | ﹤0.01% | 1523 |
|
|
2020
Q4 | $465K | Hold |
8,126
| – | – | ﹤0.01% | 1331 |
|
|
2020
Q3 | $245K | Hold |
8,126
| – | – | ﹤0.01% | 1458 |
|
|
2020
Q2 | $265K | Buy |
8,126
+3,385
| +71% | +$109K | ﹤0.01% | 1347 |
|
|
2020
Q1 | $127K | Buy |
4,741
+700
| +17% | +$24.9K | ﹤0.01% | 1467 |
|
|
2019
Q4 | $124K | Buy |
4,041
+1,657
| +70% | +$45.9K | ﹤0.01% | 1588 |
|
|
2019
Q3 | $57K | Sell |
2,384
-560
| -19% | -$15.4K | ﹤0.01% | 1942 |
|
|
2019
Q2 | $75K | Buy |
2,944
+1,099
| +60% | +$22.4K | ﹤0.01% | 1788 |
|
|
2019
Q1 | $36K | Sell |
1,845
-1,058
| -36% | -$16.6K | ﹤0.01% | 2178 |
|
|
2018
Q4 | $38K | Buy |
2,903
+1,785
| +160% | +$27.4K | ﹤0.01% | 2179 |
|
|
2018
Q3 | $20K | Buy |
+1,118
| New | +$20.7K | ﹤0.01% | 2473 |
|
Other funds holding APLS
Zurich Cantonal Bank's APLS Position: Q2 2026 in Review
Zurich Cantonal Bank sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 27,921 shares — an estimated $1.12M sold.
Zurich Cantonal Bank first reported a position in APLS in Q3 2018 and held it in 30 quarters. The position peaked at $1.2M in Q4 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Zurich Cantonal Bank reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Zurich Cantonal Bank sold 27,921 Apellis Pharmaceuticals shares in Q2 2026, an estimated $1.12M.
- Zurich Cantonal Bank first reported a position in Apellis Pharmaceuticals in Q3 2018 and held it in 30 quarters.
- Zurich Cantonal Bank's Apellis Pharmaceuticals position peaked at $1.2M in Q4 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.